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Discussion
Dr Frank W. Sellke (Boston, Mass). Can you comment on
how you performed the biopsies to make sure that there was
consistency between the TAA and AAA specimens? Because there
is so much, how do I put it, grungy material in aneurysms of both
types, especially AAAs, how did you take this into consideration?
Also, can you comment on the statistical analysis specific for
cDNA array technology?
Dr Absi. Thank you, Dr Sellke. With respect to the biopsies, I
obtained TAA specimens from the attending surgeons who were
performing the procedure, basically as a ring of tissue removed
when they had completed aneurysm repair. This tissue was snap-
frozen immediately in liquid nitrogen, and at a later time I ex-
tracted the messenger RNA. AAA repair was basically performed
by endoaneurysmorrhaphy, so in these cases I obtained a slice of
tissue along the whole length of aneurysm itself.
With respect to the statistical analysis, it is true that we did not
have a high number of blots. In going over the statistical analysis,
especially that provided with the software, our approach was in
agreement with literature reports indicating that with 5 blots one
can achieve reproducible results. Just because you are dealing with
1185 genes, the parametric analysis must be done with some
adjustments in a special kind of analysis of variance, such as the
Kruskal-Wallis test, which can be of help when you have a
relatively small number of samples.
Dr Michael J. Reardon (Houston, Tex). Congratulations on a
nice study and a nice presentation. I did have one question about
your normal samples. Were they from donors, or were they from
the recipients in transplants? Because if they came from donors,
they clearly came from much younger people, and there may be
altered gene expression with age. We have started taking some
plugs from the ascending aorta from coronaries to use those as
normal specimens. Would you comment on your normal speci-
mens?
Dr Absi. Thank you, Dr Reardon. I am glad that you brought
that up. That is an important issue, and we did not mean to
minimize it during the presentation. The pathophysiology of an-
eurysmal disease is thought to include numerous factors, age and
atherosclerosis among them. We chose to use donors for our
normal controls, who were young, because we did not want to bias
against any of these factors, namely age, in that situation. Age may
make a difference and at least some of the results we obtained may
be due to age. For this reason we are also planning in the future to
compare results in aneurysms with age-matched samples obtained
from patients undergoing coronary artery bypass grafting. How-
ever, if we had selected or stratified for age in this initial study we
would have tended to bias against it, and we did not want to do that
here.
Dr Anthony L. Estrera (Houston, Tex). This was a nice study.
My question is in relation to gender predominance. In our expe-
rience in Houston, our patients with thoracoabdominal and ascend-
ing arch repairs are primarily male, with a ratio of about 3:2;
whereas in our infrarenal replacements there is a greater male
predominance, about a 10:1 ratio. Do you have a comment? I
appreciate the small numbers in your study, but that would be
something to look at in the future.
Dr Absi. We simply chose our patients randomly over a certain
period of time during the conduct of the study, without selection
for gender, and agree that this will be an important issue to
examine in the future.
Dr Larry R. Kaiser (Philadelphia, Pa). You mentioned that
apolipoprotein E was 14-fold upregulated in, I think, the AAAs.
Are you concerned that the high concentration of apolipoprotein E
was due to contamination, perhaps by infiltrating foam cells in the
arterial wall, and did you use laser capture microdissection to
remove some of these foam cells and infiltrating leukocytes that
might have interfered?
Dr Absi. No, we did not use that technique, as this study was
not designed to identify the cell types or locations where the
changes in gene expression occurred, but only to provide a broad
survey of changes in gene expression within the tissue samples as
a whole. There are clearly a variety of different cell types present
within aneurysm tissues, including macrophages and vascular
smooth muscle cells, but the cells in which the changes in gene
expression were occurring were not examined in this initial inves-
tigation. This is another promising approach for the future.
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